New paradigms for treatment-resistant depression

Annals of the New York Academy of Sciences

Volumn 1292, Issue 1, 2013, Pages 21-31

  Zarate, Carlos ^a   Duman, Ronald S ^b   Liu, Guosong ^c   Sartori, Simone ^d   Quiroz, Jorge ^e   Murck, Harald ^f,g  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Tsinghua University   (China)

^d INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^e HOFFMANN LA ROCHE INC   (United States)

^f Dept of Stat and Clin Programming   (United States)

^g PHILIPPS UNIVERSITY MARBURG   (Germany)

Author keywords

CP AMPA; Depression; Glutamate antagonist; Glutamine; Ketamine; Magnesium; NMDA; Scopolamine; SNRI; SSRI

Indexed keywords

ADENOSINE TRIPHOSPHATASE (POTASSIUM SODIUM); ALPHA AMINO 3 HYDROXY 5 METHYL 4 ISOXAZOLEPROPIONIC ACID; AMPA RECEPTOR; BIOLOGICAL MARKER; BRAIN DERIVED NEUROTROPHIC FACTOR; CALCIUM ION; DESIPRAMINE; GLITAZONE DERIVATIVE; GLUTAMATE AMMONIA LIGASE; GLUTAMATE RECEPTOR; HYPERICUM PERFORATUM EXTRACT; IMIPRAMINE; KETAMINE; LITHIUM; MAGNESIUM; MAGNESIUM DERIVATIVE; MAGNESIUM THREONATE; MAGTEIN; MAMMALIAN TARGET OF RAPAMYCIN; METABOTROPIC RECEPTOR ANTAGONIST; METFORMIN; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; PAROXETINE; PLACEBO; S6 KINASE; SCOPOLAMINE; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; THYROTROPIN; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANHEDONIA; ANXIETY DISORDER; ARTICLE; BRAIN NERVE CELL; CARDIOVASCULAR RISK; COGNITIVE THERAPY; CONCEPTUAL FRAMEWORK; DEPRESSION; DRUG MECHANISM; EXCITATORY POSTSYNAPTIC POTENTIAL; HIPPOCAMPUS; HUMAN; INTERNEURON; MAJOR DEPRESSION; NERVE CELL PLASTICITY; NEUROIMAGING; NONHUMAN; PHARMACOGENETICS; PREFRONTAL CORTEX; QUALITY OF LIFE; REMISSION; SINGLE DRUG DOSE; SINGLE NUCLEOTIDE POLYMORPHISM; SLEEP DEPRIVATION; SUICIDE; SYNAPTOGENESIS; TREATMENT RESPONSE;

EID: 84880684441     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/nyas.12223     Document Type: Article

References (50)

1. Eby, G.A., K.L. Eby & H. Murck. 2011. Magnesium and major depression. In Magnesium in the Central Nervous System, R. Vink & M. Nechifor, Eds.: 313-330. Adelaide: University of Adelaide Press.
2. Vale, S., M.A. Espejel & J.C. Dominguez. 1971. Amantadine in depression. Lancet 2: 437.
3. Paul, I.A. & P. Skolnick. 2003. Glutamate and depression: clinical and preclinical studies. Ann. N. Y. Acad. Sci. 1003: 250-272.
4. Watkins, J.C. & D.E. Jane. 2006. The glutamate story. Br. J. Pharmacol. 147: S100-S108.
5. Schildkraut, J.J. 1965. The catecholamine hypothesis of affective disorders: a review of supporting evidence. Am. J. Psychiatry 122: 509-522.
6. Kirsch, I., T.J. Moore, A. Scoboria & S.S. Nicholls. 2002. The emperorśs new drugs: an analysis of antidepressant medication data submitted to the U.S. food and drug administration. Prevention and Treatment 5: 1-10.
7. Trivedi, M.H., A.J. Rush, S.R. Wisniewski, et al. 2006. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am. J. Psychiatry 163: 28-40.
8. Berman, R.M., A. Cappiello, A. Anand, et al. 2000. Antidepressant effects of ketamine in depressed patients. Biol. Psychiatry 47: 351-354.
9. Zarate, C.A., Jr., J.B. Singh, P.J. Carlson, et al. 2006. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch. Gen. Psychiatry 63: 856-864.
10. Duman, R.S., N. Li, R.J. Liu, et al. 2012. Signaling pathways underlying the rapid antidepressant actions of ketamine. Neuropharmacology 62: 35-41.
11. Murck, H. 2013. Ketamine, magnesium and major depression - From pharmacology to pathophysiology and back. J. Psychiatr. Res. 47: 955-965.
12. Singewald, N., C. Sinner, A. Hetzenauer, et al. 2004. Magnesium-deficient diet alters depression- and anxiety-related behavior in mice-influence of desipramine and Hypericum perforatum extract. Neuropharmacology 47: 1189-1197.
13. Miller, G. 2010. Is pharma running out of brainy ideas? Science 329: 502-504.
14. Hyman, S. 2012. Revolution stalled. Sci. Transl. Med. 4: 155
15. Institute of Medicine. 2008. Neuroscience Biomarkers and Biosignatures: Converging Technologies, Emerging Partnerships, Workshop Summary. Washington (DC).
16. Zarate, C.A., Jr., N.E. Brutsche, et al. 2012. Replication of ketamine's antidepressant efficacy in bipolar depression: a randomized controlled add-on trial. Biol. Psychiatry 71: 939-946.
17. Zarate, C.A., Jr., D.C. Mathews & M.L. Furey. 2013. Human biomarkers of rapid antidepressant effects. Biol. Psychiatry 73: 1142-1155.
18. Salvadore, G., B.R. Cornwell, et al. 2010. Anterior cingulate desynchronization and functional connectivity with the amygdala during a working memory task predict rapid antidepressant response to ketamine. Neuropsychopharmacology 35: 1415-1422.
19. Furey, M.L., W.C. Drevets, et al. 2013. Potential of pretreatment neural activity in the visual cortex during emotional processing to predict treatment response to scopolamine in major depressive disorder. JAMA Psychiatry 70: 280-290.
20. Voleti, B., A. Navarria, et al. in press. Scopolamine rapidly increases mammalian target of rapamycin complex 1 signaling, synaptogenesis, and antidepressant behavior response. Biol. Psychiatry.
21. Duman, R.S. & G.K. Aghajanian. 2012. Synaptic dysfunction in depression: Novel therapeutic targets. Science 338: 68-72.
22. Li, N., B. Lee, R.J. Liu, et al. 2010. mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science 329: 959-964.
23. Homayoun, H. & B. Moghaddam. 2007. NMDA receptor hypofunction produces opposite effects on prefrontal cortex interneurons and pyramidal neurons. J. Neurosci. 27: 11496-11500.
24. Li, N., R.J. Liu, J.M. Dwyer, et al. 2011. Glutamate N-methyl-D-aspartate receptor antagonists rapidly reverse behavioral and synaptic deficits caused by chronic stress exposure. Biol. Psychiatry 69: 754-761.
25. Liu, R.J., F.S. Lee, X.-Y. Li, et al. 2012. BDNF Met allele decreases the density and function of spine/synapses in the prefrontal cortex and blocks the effects of ketamine. Biological Psychiatry 71: 996-1005.
26. Abumaria, N., B. Yin, L. Zhang, et al. 2011. Effects of elevation of brain magnesium on fear conditioning, fear extinction, and synaptic plasticity in the infralimbic prefrontal cortex and lateral amygdala. J. Neurosci. 31: 14871-14881.
27. Li, W., J. Yu, Y. Liu, et al. 2013. Elevation of brain magnesium prevents and reverses cognitive deficits and synaptic loss in Alzheimer's disease mouse model. J. Neurosci. 33: 8423-8441.
28. Liu, G. 2004. Local structural balance and functional interaction of excitatory and inhibitory synapses in hippocampal dendrites. Nat. Neurosci. 7: 373-379.
29. Slutsky, I., S. Sadeghpour, B. Li & G. Liu. 2004. Enhancement of synaptic plasticity through chronically reduced Ca(2+) flux during uncorrelated activity. Neuron 44: 835-849.
30. Whittle, N. et al. 2011. Changes in brain protein expression are linked to magnesium restriction-induced depression-like behavior. Amino Acids 40: 1231-1248.
31. Eby, G.A., K.L. Eby & H. Murck. 2011. Magnesium and major depression. In Magnesium in the Central Nervous System, R. Vink & M. Nechifor, Eds.: 303-312. Adelaide: University of Adelaide Press.
32. Sartori, S.B. et al. 2012. Magnesium deficiency induces anxiety and HPA axis dysregulation: modulation by therapeutic drug treatment. Neuropharmacology 62: 304-312.
33. Xiong, H., T. Futamura, H. Jourdi, et al. 2002. Neurotrophins induce BDNF expression through the glutamate receptor pathway in neocortical neurons. Neuropharmacology 42: 903-912.
34. Fortin, D.A., T. Srivastava, D. Dwarakanath, et al. 2012. Brain-derived neurotrophic factor activation of CaM-kinase kinase via transient receptor potential canonical channels induces the translation and synaptic incorporation of GluA1-containing calcium-permeable AMPA receptors. J. Neurosci. 32: 8127-8137.
35. Magistretti, P.J. 2009. Role of glutamate in neuron-glia metabolic coupling. Am. J. Clin. Nutr. 90: 875S-880S.
36. 2+ influx into Retzius neurones of the leech Hirudo medicinalis. J. Gen. Physiol. 122:727-739.
37. Greenberg, J. & N. Lichtenstein. 1959. Effect of manganous and magnesium ions concentration on glutamine synthetase and glutamotransferase of sheep brain. J. Biol. Chem. 234: 2337-2339.
38. 2+ is bound to glutamine synthetase extracted from bovine or ovine brain in the presence of L-methionine-S-sulfoximine phosphate. Arch. Biochem. Biophys. 246: 494-500.
39. Feyissa, A.M., A. Chandran, C.A. Stockmeier & B. Karolewicz. 2009. Reduced levels of NR2A and NR2B subunits of NMDA receptor and PSD-95 in the prefrontal cortex in major depression. Prog. Neuropsychopharmacol. Biol. Psychiatry 33: 70-75.
40. Chatterjee, M., R. Verma, S. Ganguly & G. Palit. 2012. Neurochemical and molecular characterization of ketamine-induced experimental psychosis model in mice. Neuropharmacology
41. Burgdorf, J., X.L. Zhang, K.L. Nicholson, et al. 2013. GLYX-13, a NMDA receptor glycine-site functional partial agonist, induces antidepressant-like effects without ketamine-like side effects. Neuropsychopharmacology 38:729-742.
42. Yamada, S., M. Yamamoto, H. Ozawa, et al. 2003. Reduced phosphorylation of cyclic AMP-responsive element binding protein in the postmortem orbitofrontal cortex of patients with major depressive disorder. J. Neural Transm. 110: 671-680.
43. Teyssier, J.R., S. Ragot, Chauvet-J.C. Gelinier, et al. 2011. Activation of a DeltaFOSB dependent gene expression pattern in the dorsolateral prefrontal cortex of patients with major depressive disorder. J. Affect Disord. 133:174-178.
44. Reus, G.Z., R.B. Stringari, K.F. Ribeiro, et al. 2011. Ketamine plus imipramine treatment induces antidepressant-like behavior and increases CREB and BDNF protein levels and PKA and PKC phosphorylation in rat brain. Behav. Brain Res. 221: 166-171.
45. Dwivedi, Y., J.S. Rao, H.S. Rizavi, et al. 2003. Abnormal expression and functional characteristics of cyclic adenosine monophosphate response element binding protein in postmortem brain of suicide subjects. Arch. Gen. Psychiatry 60: 273-282.
46. Choudary, P.V., M. Molnar, S.J. Evans, et al. 2005. Altered cortical glutamatergic and GABAergic signal transmission with glial involvement in depression. Proc. Natl. Acad. Sci. USA 102: 15653-15658.
47. Huang, C.Y., Y.F. Liou, S.Y. Chung, et al. 2010. Role of ERK signaling in the neuroprotective efficacy of magnesium sulfate treatment during focal cerebral ischemia in the gerbil cortex. Chin. J. Physiol. 53:299-309.
48. Shu, L., T. Li, S. Han, et al. 2012. Inhibition of neuron-specific CREB dephosphorylation is involved in propofol and ketamine-induced neuroprotection against cerebral ischemic injuries of mice. Neurochem. Res. 37:49-58.
49. 2+ is bound to glutamine synthetase extracted from bovine or ovine brain in the presence of L-methionine-S-sulfoximine phosphate. Arch. Biochem. Biophys. 246: 494-500.
50. Rowland, L.M., J.R. Bustillo, P.G. Mullins, et al. 2005. Effects of ketamine on anterior cingulate glutamate metabolism in healthy humans: a 4-T proton MRS study. Am. J. Psychiatry 162: 394-396.